Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
February 7, 2017
Cystic fibrosis radiographic biomarkers - Commentary
Anthony G Durmowicz
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
June 22, 2016
CF end point commentary
Anthony G Durmowicz
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
November 16, 2016
Cystic fibrosis biomarker - Commentary
Anthony G Durmowicz
Annals of the American Thoracic Society
|
December 10, 2015
Tiotropium Respimat Is Effective for the Treatment of Asthma at a Dose Lower Than That for Chronic Obstructive Pulmonary Disease
Stacy J Chin, Anthony G Durmowicz, Badrul A Chowdhury
Chest
|
January 2, 2013
Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience
Anthony G Durmowicz, Kimberly A Witzmann, Curtis J Rosebraugh, et al.
Chest
|
October 2, 2013
Response
Anthony G Durmowicz, Kimberly A Witzmann, Curtis J Rosebraugh, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
December 5, 2006
Elastin protein levels are a vital modifier affecting normal lung development and susceptibility to emphysema
Adrian Shifren, Anthony G Durmowicz, Russell H Knutsen, et al.
Annals of the American Thoracic Society
|
October 12, 2017
The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial
Anthony G Durmowicz, Robert Lim, Hobart Rogers, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
September 6, 2008
Elastin insufficiency predisposes to elevated pulmonary circulatory pressures through changes in elastic artery structure
Adrian Shifren, Anthony G Durmowicz, Russell H Knutsen, et al.
The New England Journal of Medicine
|
December 16, 2011
The risks and benefits of indacaterol--the FDA's review
Badrul A Chowdhury, Sally M Seymour, Theresa M Michele, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
February 7, 2017
Cystic fibrosis radiographic biomarkers - Commentary
Anthony G Durmowicz
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
June 22, 2016
CF end point commentary
Anthony G Durmowicz
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
November 16, 2016
Cystic fibrosis biomarker - Commentary
Anthony G Durmowicz
Annals of the American Thoracic Society
|
December 10, 2015
Tiotropium Respimat Is Effective for the Treatment of Asthma at a Dose Lower Than That for Chronic Obstructive Pulmonary Disease
Stacy J Chin, Anthony G Durmowicz, Badrul A Chowdhury
Chest
|
January 2, 2013
Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience
Anthony G Durmowicz, Kimberly A Witzmann, Curtis J Rosebraugh, et al.
Chest
|
October 2, 2013
Response
Anthony G Durmowicz, Kimberly A Witzmann, Curtis J Rosebraugh, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
December 5, 2006
Elastin protein levels are a vital modifier affecting normal lung development and susceptibility to emphysema
Adrian Shifren, Anthony G Durmowicz, Russell H Knutsen, et al.
Annals of the American Thoracic Society
|
October 12, 2017
The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial
Anthony G Durmowicz, Robert Lim, Hobart Rogers, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
September 6, 2008
Elastin insufficiency predisposes to elevated pulmonary circulatory pressures through changes in elastic artery structure
Adrian Shifren, Anthony G Durmowicz, Russell H Knutsen, et al.
The New England Journal of Medicine
|
December 16, 2011
The risks and benefits of indacaterol--the FDA's review
Badrul A Chowdhury, Sally M Seymour, Theresa M Michele, et al.
Page
of 2